Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

258
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
258
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

347
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
347
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

217
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
217
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

493
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
493
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

483
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
483
Pharmacovigilance01:19

Pharmacovigilance

1.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Malaria Vaccine Implementation Programme reduced clinical malaria in Kenya, 2020 to 2022 : Impact evaluation with predictive time-series models of routine surveillance data.

Malaria journal·2026
Same author

Time to Progress Through the Latent Tuberculosis Infection Care Cascade in Primary Care.

Public health reports (Washington, D.C. : 1974)·2026
Same author

Latent tuberculosis infection care cascade outcomes in primary care clinics in the tuberculosis epidemiologic studies consortium-III.

Annals of epidemiology·2026
Same author

Tuberculosis before and during COVID-19 Pandemic, United States, 2010-2023.

Emerging infectious diseases·2026
Same author

Trends in Daily Fruit and Vegetable Intake Among Young Children in the United States, 2021-2023.

Public health reports (Washington, D.C. : 1974)·2026
Same author

Fruit and vegetable intake among rural populations in the United States, by sociodemographic characteristics, behavioral risk factor surveillance system 2019, 2021.

Nutrition and health·2025

Related Experiment Video

Updated: Sep 29, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K

Decrease in Tuberculosis Cases during COVID-19 Pandemic as Reflected by Outpatient Pharmacy Data, United States,

Kathryn Winglee, Andrew N Hill, Adam J Langer

    Emerging Infectious Diseases
    |March 23, 2022
    PubMed
    Summary
    This summary is machine-generated.

    The coronavirus disease pandemic in 2020 saw a 20% decline in reported tuberculosis (TB) cases. Pharmacy data suggests this was not due to underreporting but may indicate underdiagnosis or an actual decrease in TB cases.

    Keywords:
    COVID-19SARIMASARS-CoV-2United Statesbacteriacoronavirus diseaseprescriptionsrespiratory infectionssevere acute respiratory syndrome coronavirus 2surveillancetuberculosis and other mycobacteriaviruseszoonoses

    More Related Videos

    Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
    08:54

    Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

    Published on: May 19, 2020

    7.9K
    A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
    10:29

    A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

    Published on: March 24, 2017

    8.0K

    Related Experiment Videos

    Last Updated: Sep 29, 2025

    An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
    09:34

    An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

    Published on: August 16, 2021

    1.9K
    Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
    08:54

    Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

    Published on: May 19, 2020

    7.9K
    A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
    10:29

    A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

    Published on: March 24, 2017

    8.0K

    Area of Science:

    • Public Health
    • Epidemiology
    • Infectious Disease Surveillance

    Background:

    • The coronavirus disease (COVID-19) pandemic impacted global health systems.
    • A significant decline in reported tuberculosis (TB) cases was observed in the US during 2020.

    Purpose of the Study:

    • To analyze a pharmacy dataset to assess the reported decline in TB cases during the COVID-19 pandemic.
    • To investigate the correlation between TB medication dispensing and case counts.
    • To understand the mechanisms behind the 2020 TB case decline.

    Main Methods:

    • Analysis of a pharmacy dataset alongside US National Tuberculosis Surveillance System (NTSS) data.
    • Utilized a seasonal autoregressive integrated moving average (SARIMA) model to predict expected 2020 TB case counts.
    • Correlated TB medication dispensing trends with NTSS data from 2006-2019.

    Main Results:

    • A 20% decrease in reported TB cases in 2020 compared to the 2016-2019 average.
    • Fewer TB prescriptions and cases were observed in 2020 than predicted by historical trends.
    • The decline was most pronounced during April-May 2020.

    Conclusions:

    • The observed decline in reported TB cases is consistent with pharmacy data, suggesting no evidence of underreporting.
    • The data does not rule out potential underdiagnosis or an actual decrease in TB incidence.
    • Understanding the reasons for the decline is crucial for future TB program preparedness.